Gotowa bibliografia na temat „Gliomes – Radiothérapie”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Gliomes – Radiothérapie”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Gliomes – Radiothérapie"
Bailleul, Quentin, Andria Rakotomalala, Isabelle Ferry, Pierre Leblond, Samuel Meignan i Alessandro Furlan. "L’art de la guerre appliqué aux DIPG". médecine/sciences 37, nr 2 (luty 2021): 159–66. http://dx.doi.org/10.1051/medsci/2020279.
Pełny tekst źródłaMazeron, Jean-Jacques, Sophie Taillibert i Charles-Ambroise Valéry. "Gliomes récidivants: existe-t-il une indication de radiothérapie en conditions stéréotaxiques ?" Neurologie.com 1, nr 4 (czerwiec 2009): 98–99. http://dx.doi.org/10.1684/nro.2008.0036.
Pełny tekst źródłaAtallah, V., F. Gariel, P. Gillon, A. Crombé i J. J. Mazeron. "Radiothérapie des gliomes chez l’adulte : quels sont les enjeux de la surveillance ?" Cancer/Radiothérapie 19, nr 6-7 (październik 2015): 603–9. http://dx.doi.org/10.1016/j.canrad.2015.05.012.
Pełny tekst źródłaClavier, J. B., J. Voirin, P. Kehrli i G. Noël. "Radiothérapie en conditions stéréotaxiques des gliomes de haut grade : une revue de la littérature". Cancer/Radiothérapie 14, nr 8 (grudzień 2010): 739–54. http://dx.doi.org/10.1016/j.canrad.2010.03.021.
Pełny tekst źródłaLafon, M., A. Huchet, C. Bronnimann, S. Adgie, M. Martin, R. Trouette, V. Jecko, T. Wavasseur, C. Dupin i V. Vendrely. "Réirradiation des rechutes de gliomes de haut grade après un premier radiothérapie et témozolomide". Cancer/Radiothérapie 22, nr 6-7 (październik 2018): 707. http://dx.doi.org/10.1016/j.canrad.2018.07.041.
Pełny tekst źródłaCohen-Jonathan Moyal, É. "Optimisation de la radiothérapie des gliomes : espoirs et voies de recherche pour les années à venir". Revue Neurologique 167, nr 10 (październik 2011): 656–60. http://dx.doi.org/10.1016/j.neurol.2011.07.001.
Pełny tekst źródłaMagnin, V., C. Kintzinger, J. D. Harms, S. Taha, P. Gauchez, M. Bintner, E. Chirpaz i D. Khelif. "Premiers résultats de la radiothérapie associée à l’hyperbarisme et au témozolomide pour les gliomes de haut grade". Cancer/Radiothérapie 16, nr 5-6 (wrzesień 2012): 570. http://dx.doi.org/10.1016/j.canrad.2012.07.149.
Pełny tekst źródłaLe Tinier, F., S. Meignan, P. Leblond, A. Dewitte, N. Wattez, É. Lartigau i A. Lansiaux. "Étude des effets d’un nouvel inhibiteur d’intégrines et de son association avec la radiothérapie sur des lignées de gliomes pédiatriques". Cancer/Radiothérapie 15, nr 6-7 (październik 2011): 613–14. http://dx.doi.org/10.1016/j.canrad.2011.07.149.
Pełny tekst źródłaDalloz, P., J. Biau, A. F. Dillies, X. Durando, J. L. Kemeny, T. Khalil, F. Kwiatkowski, Y. Toledano i P. Verrelle. "Radiothérapie des gliomes de haut grade chez les patients de plus de 70ans : étude rétrospective sur 80 patients, résultats et facteurs pronostiques". Cancer/Radiothérapie 16, nr 5-6 (wrzesień 2012): 569. http://dx.doi.org/10.1016/j.canrad.2012.07.146.
Pełny tekst źródłaBernier, V., C. Kalifa, F. Doz, J. C. Gentet, C. Alapetite, S. Hoffstetter i P. Chastagner. "Association concomitante radiothérapie/topotécan dans le traitement des gliomes malins du tronc cérébral chez l’enfant. Résultats d’un essai de phase II de la SFOP". Neurochirurgie 51, nr 1 (luty 2005): 52. http://dx.doi.org/10.1016/s0028-3770(05)83430-7.
Pełny tekst źródłaRozprawy doktorskie na temat "Gliomes – Radiothérapie"
Gimenez, Paul. "Radiothérapie par photoactivation de nanoparticules et effet Mössbauer". Thesis, Université Grenoble Alpes (ComUE), 2015. http://www.theses.fr/2015GREAS038/document.
Pełny tekst źródłaAn efficient radiotherapy needs a localized dose to the tumour, which means a high contrast between tumorous and healthy tissues. A synchrotron low energy monochromatic irradiation of a tumour charged in high-Z elements allows maximizing photoelectric interactions in the tumour and spare the healthy tissues. Photoelectrons and high LET Auger electrons thus produced deposit their energy locally, enhancing radiation dose to tumor cells. Another interaction allows to enhance the dose by Auger electrons: the Mössbauer effect. This resonant and recoilless interaction specific to some isotopes like 57Fe has a cross section 450 times bigger than photoelectric effect. This thesis evaluates the in vitro use of magnetite nanoparticles combined with those 2 types of interactions. The nanoparticles evaluated present a high internalisation and a perinuclear distribution inside F98 cells. A dose-enhancement factor of 3 was obtained by photo activation of the iron Nps, this represents a huge increase. This multidisciplinary work encompasses experiments in chemistry, physics and biology in order to evaluate the applications of magnetite nanoparticles to radiotherapy
Ouedraogo, Zangbewende guy. "Rôle de l'activation de STAT3 dans l'agressivité des glioblastomes. : Cancérologie expérimentale". Thesis, Clermont-Ferrand 1, 2014. http://www.theses.fr/2014CLF1MM26/document.
Pełny tekst źródłaGliomas are tumors of the central nervous system. The highest degree in glioma malignancy is Glioblastoma (GBM) that is the most frequent of the brain cancers. GBM patients are treated by surgery at first (if it is possible), followed by radiotherapy and concomitant and adjuvant temozolomide. However, this treatment is not curative in part because GBM cells display an outstanding primary radioresistance. The JAK/STAT3 (Janus Kinase/Signal Transducer and Activator of Transcription 3) signaling pathway seems to be involved in the GBM aggressiveness. STAT3 is an intracellular signal transducer protein. It is activated by phosphorylation on its tyrosine 705 (pSTAT3-Y705) and serine 727 (pSTAT3-S727) residues. The tyrosine 705 activation is produced downstream the signal induced by the binding of interleukine-6 (IL-6) cytokine to its gp130-IL-6Rα transmembrane receptor complex. The mechanisms of the serine 727 phosphorylation are less characterized. The role of STAT3 activation in the radioresistance of GBM was studied here. Basal levels of pSTAT3-Y705, pSTAT3-S727 and intrinsic radioresistance were evaluateded in a panel of 15 GBM cel lines. Activation of STAT3 in the glioma cell lines was assessed by western blotting and radioresistance through cell surviving fraction to irradiation. In addition to the description of the basal activation of STAT3 in the glioma cell lines, this study evidenced, for the first time, a correlation between pSTAT3-S727 and GBM intrinsic radioresistance. Using a pharmacological inhibition strategy, we identified Gö6976 as a chemical blocking Y705 phosphorylation of STAT3 in GBM cells. Gö6976 also inhibited pSTAT3-S727 but only in the pSTAT3-Y705-negative cell lines. Treating GBM cell with Gö6976 slowed their growth regardless of STAT3 activation status. Interestingly, Gö6976 showed a highly significant radiosensitizing effect on pSTAT3-Y705-negative cell lines that was consistent with the down-modulation of pSTAT3-S727. The relevance of these results is strengthened by immunohistochemical assay performed of GBM clinical samples that showed a variable level of pSTAT3-S727 positive staining in all tumor cells of all the patients. Furthermore, we are currently running on an in vitro study of the pSTAT3-S727 biological function by the mean of STAT3 dominant positive and dominant negative proteins. In summary, we showed that pSTAT3-S727 is involved in the intrinsic radioresistance and that pSTAT3-Y705 is a negative predicting marker of GBM cell response to Gö6976 as both a pSTAT3-S727 inhibitor and a radiosensitizer. Altogether, our results strengthen the clinical relevance of a specific inhibition of pSTAT3-S727 to radiosensitize GBM and then improve the patient treatment
Adam, Jean-François. "Tumeurs cérébrales & rayonnement synchrotron : développements méthodologiques en imagerie quantitative de la perfusion et en radiothérapie renforcée par effet photo-électrique". Université Joseph Fourier (Grenoble), 2003. http://www.theses.fr/2003GRE19010.
Pełny tekst źródłaHigh-grade gliomas are the most frequent type of primary brain tumors in adults. Unfortunately, the management of glioblastomas is still mainly palliative and remains a difficult challenge, despite advances in brain tumor molecular biology and in some emerging novel therapies. Synchrotron radiation opens new fields for medical imaging and radiation therapy by using monochromatic intense x-ray beams. It is now well known that angiogenesis plays a critical role in the tumor growth process and that brain perfusion is representative of the tumor mitotic activity. Synchrotron Radiation Quantitative Computed Tomography is one of the most accurate techniques for measuring in vivo contrast agent concentration and thus computing precise and accurate absolute values of the brain perfusion key parameters. In conventional radiotherapy, treatment of brain tumors remains a delicate challenge, because the damages to the surrounding normal brain tissue limit the amount of radiation that can be delivered. One strategy to overcome this limitation is to infuse an iodinated contrast agent to the patient during the irradiation. The contrast agent accumulates in the tumor, through the broken blood brain barrier, and the irradiation is performed with kilovoltage X-rays, in tomographic mode, the tumor being located at the center of rotation and the beam size adjusted to the tumor dimensions. The dose enhancement results from the photoelectric effect on the heavy element and from the irradiation geometry. Synchrotron beams, providing high intensity, tunable monochromatic X-rays, are ideal for this treatment. The beam properties allow the selection of monochromatic irradiation, at the optimal energy, for a maximal dose deposit in the tumor, while sparing healthy tissues. The two complementary methods developed in this thesis offer new perspectives in the understanding of glioma growth process and in their treatment by radiation therapy. They show the potential of synchrotron radiation for absolute brain perfusion imaging, and for new therapeutic modalities using intense monochromatic X-rays
Pinel, Sophie. "Conséquences de l'érythropoiétine recombinante humaine sur l'hypoxie tumorale et l'efficacité de la radiothérapie sur deux gliomes malins humains xénogregreffés". Nancy 1, 2004. http://docnum.univ-lorraine.fr/public/SCD_T_2004_0256_PINEL.pdf.
Pełny tekst źródłaCalmon, Raphael. "IRM multimodale sériée dans les gliomes infiltrants du tronc cérébral chez l'enfant". Thesis, Paris 6, 2017. http://www.theses.fr/2017PA066462/document.
Pełny tekst źródłaDiffuse Intrinsic Pontine Glioma is a pediatric tumor with very poor prognosis. Median survival is 9-12 months. Its typical MRI appearance allows for diagnosis without histological confirmation, but has limited understanding its pathophysiology for years. DIPGs molecular identity identified as histone H3K27M mutations in 2012 defined them as a separate entity. Two subgroups with different phenotypes and prognoses are associated with mutations in one of the two variants H3.1/H3.3 of histone H3. The aim of this thesis was to use multimodal imaging techniques to better understand the pathophysiology of DIPG, by observing the evolution of the effects of different treatments over time. 1st, we showed an increase in perfusion indices associated with decreased edema after radiotherapy. Secondly, we have described the phenomenon of pseudo-progression in MRI, an increase in tumor volume and enhancement associated with a significant increase in perfusion index. This shouldn’t be confused with true tumor progression. The ratio of increase in lesion’s blood flow after radiotherapy has high sensitivity and specificity to identify pseudo-progression. 3rd, we compared the imaging parameters with the histological data to better understand the differences between the histone mutations. The mutated tumors H3.1 have more edema, more necrosis and a lower perfusion. While mutated H3.3 tumors have a higher tumor burden. Tumor burden is positive correlated to lesion blood volume. Multimodal imaging is essential in monitoring and understanding the physiopathological mechanisms of DIPG. It should be included in the research protocols in order to advance and then one day to cure these small patients
Deman, Pierre. "Tumeurs cérébrales et rayonnement Synchrotron. Développement méthodologique pour la radiothérapie par minifaisceaux et suivi du traitement par imagerie fonctionnelle". Phd thesis, Université de Grenoble, 2012. http://tel.archives-ouvertes.fr/tel-00682877.
Pełny tekst źródłaLaprie, Anne. "Imagerie métabolique par spectrométrie de résonnance magnétique des tumeurs gliales de haut-grade irradiées de l'adulte et de l'enfant". Toulouse 3, 2007. http://www.theses.fr/2007TOU30332.
Pełny tekst źródłaVanpouille-Box, Claire. "Les nanocapsules lipidiques chargées en Rhénium-188 : nouvel outil pour la radiothérapie interne du carcinome hépatocellulaire et du gliome". Phd thesis, Université d'Angers, 2011. http://tel.archives-ouvertes.fr/tel-00664659.
Pełny tekst źródłaRoullin, Valérie-Gaëlle. "Traitement des gliomes malins par implantation stéréotaxique de microsphères chargées en 5-fluorouracile : Suivi in vivo de l'efficacité du traitement par Imagerie par Résonance Magnétique". Angers, 2001. http://www.theses.fr/2001ANGE0508.
Pełny tekst źródłaRousseau, Julia. "Chimio-radiothérapie des tumeurs cérébrales : intérêt de l'injection intratumorale de drogues antinéoplasiques". Phd thesis, Grenoble 1, 2007. http://tel.archives-ouvertes.fr/tel-00274902.
Pełny tekst źródła